Quantcast

GSK Articles

Lung Disease Drug Trials Point Toward Approval Lung Disease Drug Trials Point Toward Approval
· 1

GlaxoSmithKline (GSK) this week announced that phase III of trials for its new long-acting muscarinic antagonist/long-acting beta2 agonist (LAMA/LABA) drug are complete. The drug, which is administered via inhaler, is a once-daily medicine for treatment of chronic obstructive pulmonary disease …